



SAURABH TIWARI

Partner

 (+91) 9717594168  stiwari@cspartner.in  <https://www.cspartners.in/>  <https://www.linkedin.com/in/saurabh-tiwari-55048b314>

PROFESSIONAL MEMBERSHIP

- Bar Council of Delhi

EXPERTISE

- Corporate M&A
- Commercial Transactions
- Securities Laws & Regulations
- Foreign Exchange Laws
- RBI Laws & Financial Regulations

EDUCATION

- B.Sc. LLB. (Hons. in Corporate Laws), National Law University, Jodhpur

BRIEF PROFILE

Saurabh Tiwari is a Partner at the Firm in the Corporate M&A, Securities and Regulatory Practice and specialises in Corporate M&A and commercial transactions with over 17 years of experience. He has advised on several Mergers & Acquisition transactions, some of them being the largest in specific sectors. Saurabh extensively advises international and domestic clients on Securities laws, Indian Foreign Exchange laws, Company law, RBI's regulatory framework for financial entities including NBFCs, foreign contributions law, and commercial transactions.

He has advised several foreign corporates on India market entry, foreign investments in Indian companies (FDI, including in retail, e-commerce, pharmaceutical and financial sector space) and on Overseas Direct Investments (ODI) by Indian companies. On Securities law, he regularly advises on Listing Obligations & Disclosure Requirements (LODR), Take Over Regulations, Insider Trading and Fraudulent and Unfair Trade Practices Regulations.

He regularly represents clients before the Securities and Exchange Board of India (SEBI), Reserve Bank of India (RBI) and Directorate of Enforcement (ED).

INDICATIVE DEAL EXPERIENCE

- **Viatrix (formerly Mylan)**, a US headquartered global pharmaceutical company) on acquisition of **Agila Specialties** (injectables business) from **Strides Arcolab India** (listed company).
 - **Viatrix (formerly Mylan)** on acquisition of the female healthcare business of **Famy Care Limited** (listed company).
 - **Baxter, USA** (a US headquartered global pharmaceutical company) on acquisition of Claris Injectables from **Claris Lifesciences Limited** (listed company).
 - **Vishwa Samudra Group** (a leading Engineering and Construction group), on its exit from **Navayuga Group** and on terms of family settlement towards such exit.
 - **Vishwa Samudra Group**, on its joint venture (JV) with **Adani Ports & SEZ Limited** for Krishnapatnam Port. Also advised on subsequent exit of Vishwa Samudra Group from **Krishnapatnam Port**.
 - **Biomerieux SA**, a France headquartered diagnostics company, on acquisition of substantial stake in **RAS Lifesciences Private Limited**, India (engaged in in-vitro diagnostics), and on de-merger of manufacturing division of RAS Lifesciences into Biomerieux India.
 - **Minda Corporation Limited** (listed company) on its JV with **Stoneridge Inc., US**, technology license agreements, and on exit of Stoneridge from the JV by sale of shareholding to Minda.
 - **Minda Corporation Limited** (a listed company) on its JV with INFAC, Republic of Korea and allied technology license agreements.
 - **An Indian mobile phone manufacturer** on exit of a foreign investor pursuant to tendering of securities in a potential Initial Public Offering (IPO).
 - **A leading US Banking entity** on permissible voting arrangements in relation to Global Depository Receipts (GDRs) and the legal framework governing GDRs.
 - **Dish TV & its Independent Directors**, on Indian Securities Laws and Take Over Code issues.
 - **Various luxury clothing brands and sports brands** with respect to India market entry strategy, given the norms in the single brand retail trade, multi brand retail trade and e-commerce space.
 - **Iron Mountain, US & various US based Listed Companies** on commercial terms of, drafting and implementation of ESOP schemes (including Restricted Stock Units (RSUs), Stock Appreciation Rights (SARs) and regular ESOPs) for officials of their subsidiaries and group companies in India.
-
-